Stock Crash: Q3 results were released, a setback so severe that shares plunged 18%.

News Topical, Digital Desk : Stock Crash: As soon as the company released its December quarter results (Q3 results), the shares plunged more than 18%, causing significant losses for investors, and now investors are worried. This is the same company whose stock has been falling continuously. However, management expressed confidence about the coming years.
Onesource Speciality Pharma Stock Crash News
Onesource Speciality Pharma Limited's shares witnessed a sharp fall. The main reason for the fall in the shares was the delay in regulatory approval for Semaglutide in Canada, which had a direct impact on the company's revenue and profits. According to the company, due to the delay in approval of Semaglutide, there was a huge decline in revenue in this quarter. Operating leverage also deteriorated due to weak topline, while operating expenses increased on yearly basis. Apart from this, the impact of the new Labour Code also put pressure on the margins.

Q3FY26: EBITDA declines to ₹173.22 million
Speaking of Onesource Specialty Pharma's Q3 results, the company's revenue was ₹290.34 million, a 23% decline compared to the previous quarter. EBITDA declined to ₹173.22 million, a 84% quarter-on-quarter decline. EBITDA margin also fell to 6.0%, reflecting a 79% decline. Management described Q3 as a subdued quarter, but stated that fundamental demand trends remain strong. According to the company, the order book continues to grow, and interest in the biologics segment is also increasing. The company has added another biosimilar player to the platform, strengthening confidence in the platform. Onesource Specialty Pharma share price is currently trading at ₹1,165, down 18.67%. It has declined by 31.76 per cent in the last 5 days, 34.45 per cent in 1 month, 41.88 per cent in 6 months, 41.88 per cent in 1 year and 31.58 per cent in 5 years. 

Company Guidance Despite the weak quarter, the company has reiterated its guidance for FY28. Management expects organic revenue to reach Rs 40,000 crore, which could go up to Rs 50,000 crore with the proposed acquisition. EBITDA margin has been maintained at 40 per cent, while net debt to EBITDA has been targeted to be below 1.5x. Going forward, the management has pointed to several growth drivers. These include increasing demand for GLP-1 globally, especially as Semaglutide is going off patent in over 130 countries. Additionally, end-to-end CDMO partnerships and the expansion of the biologics platform are also expected to support growth. More than 70% of the company's business comes from existing customers, providing visibility into revenue. 

Read More: Stock Market 27 January: The stock market lost steam; Sensex fell 400 points, Nifty also in the red